A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications
Condition: Duchenne Muscular Dystrophy Interventions: Drug: Casimersen; Drug: Eteplirsen; Drug: Golodirsen Sponsors: Kevin Flanigan; Sarepta Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials